GlassScriptPhysician profile
Padman A Menon
NPI 1164533386
$3,544.01
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $646 · 2021: $759 · 2022: $979.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,467.78 | 2019-2022 | |
| Genzyme Corporation | $273.59 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $250.02 | 2019-2022 | |
| Leo Pharma INC. | $231.40 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $207.84 | 2020 | |
| Incyte Corporation | $145.78 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Amgen INC. | $109.51 | 2019-2022 | |
| Pfizer INC. | $87.37 | 2019-2022 | |
| Celgene Corporation | $85.22 | 2019 | |
| Janssen Biotech, INC. | $84.66 | 2019-2022 | |
| Lilly USA, LLC | $68.29 | 2019-2022 | |
| Genentech USA, INC. | $66.80 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $49.32 | 2019 | |
| Aclaris Therapeutics, INC. | $47.41 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $41.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $40.58 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.80 | 2020 | |
| Epi Health, LLC | $29.84 | 2019 | |
| Organogenesis INC. | $26.11 | 2021 | |
| Ucb, INC. | $18.39 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.05 | 2019 | |
| Galderma Laboratories, L.P. | $15.78 | 2019 | |
| Next Science LLC | $12.68 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $11.80 | 2019 |
Research and ownership
$3,870.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padman Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.